MX2023008219A - Derivados de pirazolo[3,4-d]pirimidin-6-il-sulfonamida para la inhibición de la serina/treonina proteina cinasa (sgk-1). - Google Patents
Derivados de pirazolo[3,4-d]pirimidin-6-il-sulfonamida para la inhibición de la serina/treonina proteina cinasa (sgk-1).Info
- Publication number
- MX2023008219A MX2023008219A MX2023008219A MX2023008219A MX2023008219A MX 2023008219 A MX2023008219 A MX 2023008219A MX 2023008219 A MX2023008219 A MX 2023008219A MX 2023008219 A MX2023008219 A MX 2023008219A MX 2023008219 A MX2023008219 A MX 2023008219A
- Authority
- MX
- Mexico
- Prior art keywords
- sgk
- pyrazolo
- pyrimidin
- inhibition
- sulfonamide derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163136782P | 2021-01-13 | 2021-01-13 | |
| US202163262040P | 2021-10-04 | 2021-10-04 | |
| PCT/CA2022/050038 WO2022150911A1 (en) | 2021-01-13 | 2022-01-12 | Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023008219A true MX2023008219A (es) | 2023-08-24 |
Family
ID=82446316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023008219A MX2023008219A (es) | 2021-01-13 | 2022-01-12 | Derivados de pirazolo[3,4-d]pirimidin-6-il-sulfonamida para la inhibición de la serina/treonina proteina cinasa (sgk-1). |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240309005A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4277905A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024502178A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230136622A (cg-RX-API-DMAC7.html) |
| CN (2) | CN121517419A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023008219A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022150911A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3261470A1 (en) * | 2022-07-12 | 2024-01-18 | Thryv Therapeutics Inc. | N-[4-(4-[[2-(DIMETHYLAMINO)ETHYL]AMINO]-3-METHYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL)-2-FLUOROPHENYL]-2,5-DIFLOOROBENZENESULFONAMIDE SALTS AND THEIR CRYSTALLINE FORMS |
| WO2024015055A1 (en) * | 2022-07-13 | 2024-01-18 | Thryv Therapeutics Inc. | Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1 and treatment of cancer |
| KR102912267B1 (ko) * | 2023-04-20 | 2026-01-15 | 한국화학연구원 | 신규한 헤테로고리 화합물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물 |
| EP4784582A1 (en) * | 2023-09-27 | 2026-08-05 | Bristol-Myers Squibb Company | Piperidine substituted pyrazolopyrimidine derivatives as inhibitors of sgk1 |
| WO2026107572A1 (en) * | 2024-11-21 | 2026-05-28 | Thryv Therapeutics Inc. | Salts of n-[4-(4-[[2-(dimethylamino)ethyl]amino]-3-methyl-1h-pyrazolo[3,4-d]pyrimidin-6-yl)-2-chlorophenyl]-2,5-difluorobenzenesulfonamide and crystalline forms thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5827849B2 (ja) * | 2011-09-20 | 2015-12-02 | サノフイ | N−[4−(1H−ピラゾロ[3,4−b]ピラジン−6−イル)−フェニル]−スルホンアミド及び薬剤としてのその使用 |
| TWI629275B (zh) * | 2013-03-13 | 2018-07-11 | 賽諾菲公司 | N-(4-(氮雜吲唑-6-基)-苯基)-磺醯胺及其作為醫藥之用途 |
| WO2015048531A1 (en) * | 2013-09-26 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Inhibition of sgk1 in the treatment of heart conditions |
| CA3026983A1 (en) * | 2016-06-08 | 2017-12-14 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| KR102678781B1 (ko) * | 2016-12-07 | 2024-06-27 | 오리모스 테라퓨틱스 씨오., 엘티디. | Sgk 활성을 조절하기 위한 화합물 및 약학 조성물 및 이의 방법 |
-
2022
- 2022-01-12 WO PCT/CA2022/050038 patent/WO2022150911A1/en not_active Ceased
- 2022-01-12 EP EP22738863.4A patent/EP4277905A4/en active Pending
- 2022-01-12 US US18/272,162 patent/US20240309005A1/en active Pending
- 2022-01-12 MX MX2023008219A patent/MX2023008219A/es unknown
- 2022-01-12 KR KR1020237027620A patent/KR20230136622A/ko active Pending
- 2022-01-12 CN CN202511808384.4A patent/CN121517419A/zh active Pending
- 2022-01-12 JP JP2023541702A patent/JP2024502178A/ja active Pending
- 2022-01-12 CN CN202280012928.4A patent/CN117062817B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN117062817B (zh) | 2026-07-31 |
| JP2024502178A (ja) | 2024-01-17 |
| WO2022150911A8 (en) | 2022-09-09 |
| AU2022208639A1 (en) | 2023-07-20 |
| EP4277905A1 (en) | 2023-11-22 |
| CN121517419A (zh) | 2026-02-13 |
| CA3172186A1 (en) | 2022-07-21 |
| WO2022150911A1 (en) | 2022-07-21 |
| EP4277905A4 (en) | 2025-01-01 |
| KR20230136622A (ko) | 2023-09-26 |
| US20240309005A1 (en) | 2024-09-19 |
| CN117062817A (zh) | 2023-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022150911A8 (en) | Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1 | |
| Uhrin et al. | Vascular smooth muscle cell proliferation as a therapeutic target. Part 2: Natural products inhibiting proliferation | |
| TN2022000039A1 (en) | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| MX2023010806A (es) | 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas. | |
| MY206521A (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| US9422297B2 (en) | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | |
| MX2022015703A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf. | |
| NZ766835A (en) | Pharmaceutical compounds | |
| CR20200620A (es) | Compuestos de purinona y su uso en el tratamiento del cáncer campo | |
| JP2008538546A (ja) | 低酸素選択的タンパク質キナーゼ阻害剤としての複素環n−オキシド | |
| ES2176251T3 (es) | Compuestos utilizados como inhibidores de pde iv y del factor de necrosis tumoral(tnf). | |
| WO2020210320A8 (en) | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones | |
| AR020321A1 (es) | Derivados del acido antranilico, procedimiento para prepararlos, composiciones farmaceuticas formuladas con dichos derivados; uso de dichos derivados parala fabricacion de dichas composiciones y metodo para el tratamiento de enfermedades aplicando los derivados mencionados. | |
| MX2021012223A (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria. | |
| MX2024008868A (es) | Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso. | |
| CN101484443B (zh) | 放射线治疗增强剂 | |
| NZ761680A (en) | Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors | |
| WO2024158996A3 (en) | Exatecan immunoconjugates | |
| MX2023009962A (es) | Composicion farmaceutica combinada que contiene inhibidor de cdk4/6 y su uso. | |
| CA3124938A1 (en) | Novel compound and pharmaceutical composition comprising same for enhancing anticancer activity | |
| MX2023009954A (es) | Compuestos de aminopirimidina y métodos de uso de estos. | |
| MX2025006420A (es) | Inhibidores de adar1 y métodos de uso de estos | |
| EP2382974A1 (en) | Use of cyclosquaramide compounds as anti-tumour agents | |
| CN108727341B (zh) | 一种吡咯取代吲哚酮类衍生物或其药学上可接受的盐、及它们的制备方法和用途 |